Trial · NCT05823896
ImPROving Quality of LIFe in the Long COVID Patient
NCT05823896, Phase 2, Completed, Karolinska Institutet
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ImPROving Quality of LIFe in the Long COVID Patient. Trials, record NCT05823896. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05823896
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ImPROving Quality of LIFe in the Long COVID Patient
- NCT number
- NCT05823896
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 219 participants, actual
- Lead sponsor
- Karolinska Institutet
- Conditions
Post-COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19, POTS - Postural Orthostatic Tachycardia Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Postinfectious Inflammation, Postinfectious Disorder
- Interventions
- Nirmatrelvir/ritonavir, Placebo/ritonavir
- First posted
- 2023-04-21
- Last updated
- 2024-12-04
- Other registries' IDs
- eudract:2022-003855-32
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in quality of life over time | Baseline and day 16 | The effect of oral administration of nirmatrelvir/ritonavir on quality of life measured as change from baseline using the EQ-5D-5L VAS scale. |
| Secondary | Change from baseline in quality of life over time | Baseline and days 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on quality of life measured as change from baseline using the EQ-5D-5L VAS scale. |
| Secondary | Change from baseline in hemodynamic response over time | Baseline and days 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on hemodynamic response (only patients diagnosed with postural orthostatic tachycardia syndrome, POTS). Change from baseline in delta maximum heart rate during active standing test. |
| Secondary | Change from baseline in dysautonomia over time | Baseline and days 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on dysautonomia symptoms. Change from baseline as measured using the Composite Autonomic Symptom Score (Compass31) questionnaire. |
| Secondary | Change from baseline in fever in patients with POTS over time | Baseline and days 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on fever (only patients diagnosed with POTS). Change from baseline in POTS-specific symptoms as measured by using the Malmo POTS score, MAPS. |
| Secondary | Change from baseline in endothelial function over time | Baseline and day 45 | The effect of oral administration of nirmatrelvir/ritonavir on reactive hyperemia index. Change from baseline in endothelial function measured using the EndoPat® device. |
| Secondary | Change from baseline in heart rate over time | Baseline and days 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on 24-h average heart rate. Change from baseline in heart rate using ECG monitoring device. |
| Secondary | Change from baseline in fever over time | Baseline and days 16, 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on fever. Change from baseline in body temperature. |
| Secondary | Change from baseline in physical capacity over time | Baseline and days 16, 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on physical capacity. Change from baseline as measured by 6-minute walk test. |
| Secondary | Change from baseline in handgrip strength over time | Baseline and days 16, 45 and 90 | The effect of oral administration of nirmatrelvir/ritonavir on handgrip strength. Change from baseline as measured by JAMAR hand dynamometer. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05823896
GET https://conductscience.org/api/trials/v1/NCT05823896/registered